Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.
|Articles|February 14, 2023
Genentech Breaks Ground on Manufacturing Facility
New California plant expected to streamline medicine production.
Advertisement
Genentech, a biotechnology company and member of the Roche Group, is adding a new biologics manufacturing facility to its existing campus in Oceanside, Calif. With the anticipated investment totaling $450 million, the new site will reportedly be employing digital technologies to move medicines from production to patients, both at a faster rate and more sustainably. The Oceanside campus was selected due to its proximity to a pool of biotech talent in the area.
Once it becomes operational in early 2025, the site will be the first location in the company’s global manufacturing network designed specifically for commercial production of biologics for smaller patient populations, including rare diseases and personalized medicines.
“… We remain committed to our home state of California and continue to invest in new ways to bring medicines to patients quicker and more sustainably,” notes Alexander Hardy, CEO of Genentech.
Advertisement
Related to this article
Nine more manufacturers join the MFN program, pairing new Medicaid pricing deals with $19.6B in U.S. manufacturing investment and API reserve donations.
Cencora's Ameer Ali explains how the shift to NDC-12 is reshaping supply chain systems and why readiness still varies widely across manufacturers.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.
DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
White House Extends MFN Pricing to Every State Medicaid Program
2
Pharma Pulse: Independent Pharmacies Sue Express Scripts, Novo Taps Anthropic, Pharma Joins Clean Heat
3
How Rebate Timing Distorts a Pharmacy's 340B Books
4
Pharma Pulse: Behind the Scenes of LogiPharma USA 2026
5